Sovereign Financial Group Inc. Acquires 140 Shares of Eli Lilly and Company (NYSE:LLY)

Sovereign Financial Group Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 29.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 612 shares of the company’s stock after acquiring an additional 140 shares during the quarter. Sovereign Financial Group Inc.’s holdings in Eli Lilly and Company were worth $357,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $36,000. Family CFO Inc bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $40,000. Finally, O Brien Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 70.5% during the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after buying an additional 31 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the stock. Morgan Stanley upped their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Finally, Bank of America boosted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Stock Up 1.4 %

NYSE:LLY traded up $11.09 on Tuesday, hitting $777.77. The stock had a trading volume of 2,842,407 shares, compared to its average volume of 3,088,457. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78. The firm’s fifty day simple moving average is $761.22 and its two-hundred day simple moving average is $674.88. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock has a market cap of $739.20 billion, a P/E ratio of 114.55, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.62 earnings per share. Analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.